Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2020 09:40 ET | Source: Genmab A/S

Genmab Announces Data to be Presented at the EHA25 Virtual Congress

Media Release Copenhagen, Denmark, May 14, 2020 Eight industry-sponsored abstracts featuring Genmab programs and partner programs selected for presentation at EHA25 Virtual Congress Genmab A/S...
May 12, 2020 13:11 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; May 12, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 69,090 shares as a consequence of the exercise of employee warrants. The...
May 06, 2020 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2020

May 6, 2020; Copenhagen, Denmark;Interim Report for the First Quarter Ended March 31, 2020 Highlights DARZALEX® (daratumumab) net sales increased approximately 49% compared to the first quarter of...
May 01, 2020 13:36 ET | Source: Genmab A/S

Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma

Company Announcement Subcutaneous formulation of daratumumab, DARZALEX FASPRO™, approved by the U.S. FDA for the treatment of patients with multiple myelomaApproval based on data from Phase III...
April 30, 2020 14:55 ET | Source: Genmab A/S

CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma

Company Announcement Committee for Medicinal Products for Human Use issued Positive Opinion for subcutaneous formulation of daratumumab for the treatment of patients with multiple myelomaOpinion...
April 29, 2020 15:04 ET | Source: Genmab A/S

Genmab Announces Data to be Presented at ASCO20 Virtual Scientific Program

Media Release Copenhagen, Denmark, April 29, 2020 Six industry sponsored abstracts regarding Genmab and Genmab partnered programs selected for presentation at ASCO20 Virtual Scientific Program,...
April 14, 2020 06:35 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2020

Company Announcement Net sales of DARZALEX® in the first quarter of 2020 totaled USD 937 millionGenmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark;...
April 01, 2020 16:19 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement Copenhagen, Denmark; April 1, 2020 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the...
March 31, 2020 15:43 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; March 31, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 54,425 shares as a consequence of the exercise of employee warrants. The...
March 30, 2020 17:41 ET | Source: Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Media Release Copenhagen, Denmark, March 30, 2020 Genmab filed Form 20-F for the financial year 2019 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report...